52 Search Results for Lymphoma
Limited data are available regarding the incidence, survival patterns, and long-term outcomes of natural killer/T-cell neoplasms in the United States.
Prevention of AIDS-defining cancers, such as non-Hodgkin lymphoma, can be helped by early, sustained antiretroviral therapy, which results in long-term viral suppression, a new study found.
While the availability of novel therapies is making the future brighter for non-Hodgkin’s lymphoma (NHL) patients, new treatments also are coming on line for Hodgkin’s lymphoma, which is a hematological cancer distinct from NHL.
Because several studies have suggested it fails to increase overall survival (OS) despite prolonging progression-free survival (PFS), use of maintenance rituximab (MR) following chemoimmunotherapy in follicular lymphoma (FL) remains controversial.
Bleomycin, the first line standard of care for Hodgkin lymphoma causes pulmonary events in some patients, but physicians have been uncertain how many patients are affected and how long they remain at risk.
Long-term survival in patients with aggressive peripheral T-cell lymphoma (PTCL) is generally poor, no clear consensus exists on optimal initial therapy, according to a new study.
After decades on the sidelines, research in cutaneous T-cell lymphoma (CTCL) has exploded in recent years, bringing patients with this rare disease new opportunities for treatment.
PORTLAND, OR—High response rates can be achieved with first-line high-dose methotrexate (HD-MTX) based regimens for primary central nervous system lymphoma (PCNSL), but many patients relapse within two years of diagnosis, according to a study in... View Article
Hepatitis C virus (HCV) infection is known to cause hepatocellular carcinoma (HCC) and subtypes of non-Hodgkin lymphoma (NHL).
Recent research has focused on some etiological factors to help predict who is at risk for developing cutaneous T-cell lymphoma (CTCL), which occurs disproportionately in veterans.
Presumptively caused by Agent Orange exposure, cutaneous T-cell lymphoma occurs disproportionately among male veterans. Complicating the clinical approach, the disorders comprising CTCL are similar but differ greatly in response to therapy. New genomic research on the rare cancer, however, is holding out promise for better, more-customized treatment.
ROCKVILLE, MD — While previous studies have reported that survivors of non-Hodgkin lymphoma (NHL) have an increased risk of developing cutaneous melanoma, risks associated with specific treatments and immune-related risk factors have not been quantified.To... View Article
SAN ANTONIO — New research directly links disrupted metabolism to a common and often fatal type of lymphoma, according to an article in Nature Communications.1“The link between metabolism and cancer has been proposed or inferred... View Article
As the healthcare system with the most experience treating older men, the VA has special expertise in treating uncommon diseases that plague them, such as peripheral T-cell lymphoma. The current challenge for clinicians is to... View Article
An estimated 5-10% of all cutaneous T-cell lymphoma (CTCL) diagnosed each year occurs in veterans treated by the VA. The cancer, classified as presumptively caused by Agent Orange exposure, is notoriously difficult to diagnose and... View Article
Diffuse large b-cell lymphoma accounts for approximately one-third of all cases of non-Hodgkin lymphoma, which is classified by the VA as a presumptive disease for veterans exposed to Agent Orange while serving in Vietnam.
Genetic and environmental risk factors have been associated with the development of multiple primary melanomas (MPM) but a new study questioned whether those patients might have increased predisposition to developing internal malignancies.
Thirty years ago, veterans with human immunodeficiency virus and their physicians focused on survival.
VA officials told lawmakers last month that it opposes a bill that would expand the presumption of Agent Orange exposure to Vietnam veterans who served offshore because the "science is not there."
About a third of hematologic cancer patients in a recent cohort study screened positive for executive dysfunction, and more than 17% had memory problems.